Buy Apidra SoloStar Pens (100 Units/mL)
The Apidra SoloStar Pens are a rapid-acting insulin (similar to Fiasp) that begins working 10 to 20 minutes after application. Like insulin produced in the body, it allows glucose into fat cells and muscles to have energy. In addition, it will block glucose from being released from the liver.
Apidra SoloStar Pens (100IU/ml injectable) are used to improve blood sugar levels in people with type 1 and type 2 diabetes. Fast-acting insulin effectively lowers blood sugar levels after meals and helps prevent severe diabetes complications.
Apidra is also available in vials and cartridges. Solostar pens and similar cartridges are available through the Apidra brand.
Diabetes medications or other long-acting insulin medications are typically prescribed with this medication. This insulin is to be injected subcutaneously (under the skin) by your nurse or doctor. You should exercise regularly, eat a healthy diet, and lose weight as part of your diabetes treatment.
Track your blood sugar levels regularly, and be sure to share them with your doctor so they can adjust your dosage accordingly. Your doctor may add other medications to your regimen such as Novolin and Ozempic to help better your diabetes management.
Warnings and Precautions
Patients should not share SoloStar pens, even if the needle is changed. Needles and syringes must never be shared or reused by patients who use Apidra vials. Shared devices can transmit blood-borne pathogens.
Dosage Adjustment and Monitoring
Patients on insulin therapy must monitor their glucose levels. Under medical supervision, insulin regimen changes should be made cautiously. It may be necessary to change insulin doses due to changes in insulin strength, manufacturer, type, or method of administration. It may be necessary to adjust oral antidiabetic treatment concomitantly. The time course of action for Apidra may vary among individuals or at different times within the same individual depending on many factors, including the site of injection, local blood supply, and local temperature. Changing physical activity levels or meal plans may require adjustment of insulin dosages.
Hypoglycemia
The most common side effect of insulin therapy, including Apidra, is hyperglycemia. Tighter glycemic control increases the risk of hypoglycemia. Patient education is essential to recognizing and managing hypoglycemia. Hypoglycemia can result in unconsciousness and/or convulsions, or may even cause death. Clinical trials with insulin, including trials with Apidra, have shown cases of severe hypoglycemia requiring another person’s assistance and/or parenteral glucose infusions and glucagon administration. Hypoglycemia is usually related to the time-action profiles of insulin formulations. Hypoglycemia may also be caused by other factors such as changes in food intake (e.g., amount of food or timing of meals), injection site, exercise, and concomitant medications]. With all insulin, use caution with patients who are unaware of hypoglycemia or who may be predisposed to hypoglycemia (e.g., children and people who fast or eat irregularly). As a result of hypoglycemia, the patient may have difficulty concentrating and responding. Especially in situations where these abilities are key, such as when driving or operating machinery, this can pose a risk. Patients with diabetes may experience symptoms similar to hypoglycemia when their serum glucose levels change rapidly, regardless of the glucose value. Hypoglycemia’s early warning symptoms may differ or diminish under certain conditions, including long-term diabetes, diabetic nerve disease, use of beta-blockers, or intensified diabetes control. Hypoglycemia in these situations may result in severe hypoglycemia (and, possibly, loss of consciousness) before the patient can recognize it. Insulin administered intravenously has a more rapid onset of action than insulin administered subcutaneously, requiring closer monitoring for hypoglycemia.
Hypersensitivity and Allergic Reactions
With insulin products, including Apidra, there is the possibility of life-threatening, generalized allergies, including anaphylaxis.
Hypokalemia
Apidra, like all insulin products, causes a shift in potassium between the extracellular and intracellular spaces, potentially resulting in hypokalemia. Hypokalemia untreated can cause respiratory paralysis, ventricular arrhythmia, and death. Patients who may be at risk for hypokalemia (e.g., patients taking potassium-lowering medications, patients taking medications sensitive to serum potassium levels) should be treated with caution. When Apidra is administered intravenously, monitor glucose and potassium frequently.
Renal or Hepatic Impairment
Patients with renal or hepatic impairment may require frequent glucose monitoring and insulin dose reduction.
Mixing of Insulins
Insulin preparations other than NPH insulin should not be mixed with Apidra for subcutaneous injection. When mixing Apidra with NPH insulin, Apidra should be drawn into the syringe first. Immediately follow mixing with injection. Using Apidra in a continuous subcutaneous infusion pump or intravenous administration with other insulins is not recommended. In addition to 0.9% sodium chloride (normal saline), Apidra should not be diluted with other solutions. Apidra has not been tested for efficacy and safety in external subcutaneous infusion pumps when mixed with diluents or other insulins.
Subcutaneous Insulin Infusion Pumps
Apidra must never be diluted or mixed with any other insulin when it is used in an external insulin pump for subcutaneous infusion. The reservoir of Apidra must be changed every 48 hours at the very least. Temperatures greater than 98.6°F (37°C) should not be exposed to Apidra. Hyperglycemia, ketosis, and diabetic ketoacidosis can occur rapidly when the insulin pump or infusion set malfunctions or handling errors occur. Diabetic ketoacidosis or hyperglycemia must be identified and corrected as soon as possible. Apidra is sometimes necessary for interim treatment. In addition to training to administer insulin by injection, patients using continuous subcutaneous insulin infusion pumps must have alternative insulin therapy options available.
Intravenous Administration
To avoid potentially fatal hypoglycemia and hypokalemia, glucose and potassium levels must be closely monitored when Apidra is administered intravenously. Apidra should not be mixed with other insulin for intravenous administration. Only normal saline solution can be diluted with Apidra.
Fluid Retention and Heart Failure
In patients taking thiazolidinediones (TZDs), which act as PPAR gamma agonists, fluid retention can occur, particularly in those taking insulin. Heart failure may be exacerbated or caused by fluid retention. It is important to monitor patients treated with insulin, Apidra, and PPAR-gamma agonists for signs and symptoms of heart failure. The PPAR-gamma agonist should be discontinued or reduced in dose if heart failure develops according to current guidelines.
